Nafithromycin: a pharmacological and microbiological overview of a new-generation lactone-ketolide for combating antimicrobial resistance

Guru Prasad Manderwad; Sailaxmi Venepally; RajKumar H. R. V.; Sandeep Kumar Tipparti; A. Nag Teja Pavani

doi:10.18203/2394-6040.ijcmph20262769

Authors

Guru Prasad Manderwad Department of Microbiology, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India
Sailaxmi Venepally Department of Pharmacology, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India
RajKumar H. R. V. Department of Microbiology, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India
Sandeep Kumar Tipparti 1Department of Microbiology, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India
A. Nag Teja Pavani Department of Pharmacology, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20262769

Keywords:

Nafithromycin, Community acquired pneumonia, Antimicrobial resistance, Macrolide

Abstract

There has been a rapid increase in antimicrobial resistance, particularly among respiratory pathogens, which poses a serious global challenge to the effective treatment of infectious diseases. Nafithromycin is a next-generation macrolide antibiotic and India’s first indigenously developed drug in this class, representing a major therapeutic breakthrough after more than three decades. Based on its chemical structure, nafithromycin is categorized as a lactone-ketolide. This agent demonstrates favorable pharmacokinetic and pharmacodynamic properties along with enhanced hepatic safety when compared to earlier ketolides. Nafithromycin also exhibits improved ribosomal binding and excellent lung tissue penetration. This review focuses on the pharmacological and microbiological aspects of nafithromycin, including its antimicrobial spectrum, safety profile, clinical trial data, and overall tolerability.

References

Walsh F, Willcock J, Amyes S. High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. J Antimicrob Chemother. 2003;52(3):345-53.

Pophale H. Nafithromycin: a potential ketolide antibiotic for combating antimicrobial resistance in community-acquired bacterial pneumonia. Next Res. 2025;2(3):100592.

Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46(9):2727-34.

Feldman C, Anderson R. Recent advances in the epidemiology and prevention of Streptococcus pneumoniae infections. F1000Res. 2020;9:1000.

Leclercq R. Mechanisms of resistance to macrolides and lincosamides. Clin Infect Dis. 2002;34(4):482-92.

Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.

Leclercq R. Mechanisms of resistance to macrolides and lincosamides. Clin Infect Dis. 2002;34(4):482-92.

Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46(9):2727-34.

Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. ClinTher. 2005;27(8):1144-63.

Wolter N, Smith AM, Farrell DJ, Northwood JB, Douthwaite S, Klugman KP. Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. Antimicrob Agents Chemother. 2008;52(2):435-40.

Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. P T. 2015;40(4):277-83.

World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Geneva: World Health Organization; 2014.

Telithromycin: the first ketolide antimicrobial. Clin Ther. 2005;27(8):1144-63.

Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet. 2005;44(9):915-34.

Mansour H, Chahine EB, Karaoui LR, El-Lababidi RM. Cethromycin: a new ketolide antibiotic. Ann Pharmacother. 2013;47(3):368-79.

Rafie S, MacDougall C, James CL. Cethromycin: a promising new ketolide antibiotic for respiratory infections. Pharmacotherapy. 2010;30(3):290-303.

Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert OpinInvestig Drugs. 2008;17(3):387-400.

Shukla I. Efficacy and safety of nafithromycin in community-acquired bacterial pneumonia: a phase III randomized controlled trial. Clin Infect Dis. 2024.

Kandi V. Nafithromycin: a potential ketolide antibiotic for combating antimicrobial resistance. Next Research. 2025.

Wockhardt Ltd. Approval of Nafithromycin in India. 2024. Available at: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2081506®=48&lang=2. Accessed on 3 June 2026.

Wockhardt Bio AG. Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin compared with oral moxifloxacin in community-acquired bacterial pneumonia. Monaldi Arch Chest Dis. 2025.

Sader HS, Castanheira M, Flamm RK, Mendes RE. In vitro activity of the novel lactone ketolidenafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program. Antimicrob Agents Chemother. 2017;61(11):1286-17.

Rodvold KA, Gotfried MH, Chugh R, Gupta M, Yeole R, Patel A. Comparison of plasma and intrapulmonary concentrations of nafithromycin (WCK 4873) in healthy adult subjects. Antimicrob Agents Chemother. 2017;61(9):01015-17.

Pophale H. Nafithromycin: a potential ketolide antibiotic for combating antimicrobial resistance in community-acquired bacterial pneumonia. Next Res. 2025;2(3):100592.

Chavan R, Zope V, Chavan N. Assessment of the in vitro cytochrome P450 inhibition potential of nafithromycin, a next-generation lactone ketolide antibiotic. Xenobiotica. 2021;51(6):647-56.

Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. ClinTher. 2005;27(8):1144-63.

Sader HS, Castanheira M, Flamm RK, Mendes RE. In vitro activity of the novel lactone ketolidenafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program. Antimicrob Agents Chemother. 2017;61(11):01286-17.

Chavan R, Zope V, Chavan N. Assessment of the in vitro cytochrome P450 inhibition potential of nafithromycin, a next generation lactone ketolide antibiotic. Xenobiotica. 2020;51(6):647-56.

Kulkarni P, Chavan R, Deshpande A. Preclinical safety evaluation of nafithromycin (WCK 4873) with emphasis on liver safety in rat and dog. Regul Toxicol Pharmacol. 2021;120:104861.

Nguyen M, Chung EP. Telithromycin: the first ketolide antimicrobial. ClinTher. 2005;27(8):1144-63.

Pophale H. Nafithromycin: a potential ketolide antibiotic for combating antimicrobial resistance in community-acquired bacterial pneumonia. Next Res. 2025;2(3):100592.

World Health Organization. Antimicrobial resistance: global report on surveillance 2014. Geneva: World Health Organization; 2014.

Sader HS, Castanheira M, Flamm RK, Mendes RE. In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program. Antimicrob Agents Chemother. 2017;61(11):01286-17.

Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. PT. 2015;40(4):277-83.